These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

585 related items for PubMed ID: 30851873

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Patterns of medication utilization and costs associated with the use of etanercept, adalimumab, and ustekinumab in the management of moderate-to-severe psoriasis.
    Feldman SR, Zhao Y, Navaratnam P, Friedman HS, Lu J, Tran MH.
    J Manag Care Spec Pharm; 2015 Mar; 21(3):201-9. PubMed ID: 25726029
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Efficacy and cost-efficacy of biologic therapies for moderate to severe psoriasis: a meta-analysis and cost-efficacy analysis using the intention-to-treat principle.
    Chi CC, Wang SH.
    Biomed Res Int; 2014 Mar; 2014():862851. PubMed ID: 24605338
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Cost Per Additional Responder Associated With Ixekizumab and Etanercept in the Treatment of Moderate-to-Severe Psoriasis.
    Feldman SR, Foster SA, Zhu B, Burge R, Al Sawah S, Goldblum OM.
    J Drugs Dermatol; 2017 Dec 01; 16(12):1246-1252. PubMed ID: 29240860
    [Abstract] [Full Text] [Related]

  • 31. Twelve-week secukinumab treatment is consistently efficacious for moderate-to-severe psoriasis regardless of prior biologic and non-biologic systemic treatment: Post hoc analysis of six randomised trials.
    Hampton P, Halliday A, Aassi M, Subramanian S, Jain M, Griffiths CEM.
    J Eur Acad Dermatol Venereol; 2021 Apr 01; 35(4):928-937. PubMed ID: 33030755
    [Abstract] [Full Text] [Related]

  • 32. Cost-efficacy of biologic therapies for moderate to severe psoriasis from the perspective of the Taiwanese healthcare system.
    Wang SH, Chi CC, Hu S.
    Int J Dermatol; 2014 Sep 01; 53(9):1151-6. PubMed ID: 24738910
    [Abstract] [Full Text] [Related]

  • 33. Improved effectiveness from individualized dosing of self-administered biologics for the treatment of moderate-to-severe psoriasis: a 5-year retrospective chart review from a Spanish University Hospital.
    Sanz-Gil R, Pellicer A, Montesinos MC, Valcuende-Cavero F.
    J Dermatolog Treat; 2020 Jun 01; 31(4):370-377. PubMed ID: 30924390
    [Abstract] [Full Text] [Related]

  • 34. Comparative cost-effectiveness of tildrakizumab and other commonly used treatments for moderate-to-severe psoriasis.
    Wu JJ, Jia X, Zhao Y, Carrico J, Brodtkorb TH, Mendelsohn A, Lowry S, Feldman SR, Armstrong A.
    J Dermatolog Treat; 2021 Nov 01; 32(7):693-700. PubMed ID: 32233828
    [Abstract] [Full Text] [Related]

  • 35. Number needed to treat and cost per remitter for biologic treatments of Crohn's disease in Japan.
    Ueno F, Doi M, Kawai Y, Ukawa N, Cammarota J, Betts KA.
    J Med Econ; 2020 Jan 01; 23(1):80-85. PubMed ID: 31294641
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Cost-effectiveness of tildrakizumab for the treatment of moderate-to-severe psoriasis in the United States.
    Jia X, Zhao Y, Carrico J, Brodtkorb TH, Mendelsohn AM, Lowry S, Feldman S, Wu JJ, Armstrong AW.
    J Dermatolog Treat; 2022 Mar 01; 33(2):740-748. PubMed ID: 32602762
    [Abstract] [Full Text] [Related]

  • 40. Efficacy of biologics in the treatment of moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials with different time points.
    Puig L, López A, Vilarrasa E, García I.
    J Eur Acad Dermatol Venereol; 2014 Dec 01; 28(12):1633-53. PubMed ID: 24033851
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 30.